TABLE 5.

Parkinson’s disease medication usage patterns

	N	Carbidopa/levodopa (Sinemet)	Dopamine agonists*	COMT inhibitors**
Men
PD subtype
Akinetic-rigid	46	23 (50.0)	20 (43.5)	4 (8.7)
Mixed	10	4 (40.0)	3 (30.0)	2 (20.0)
Tremor-dominant	36	8 (22.2)	20 (55.6)	1 (2.8)
Age at exam (yr)
<60	19	3 (15.8)	13 (68.4)	2 (10.5)
60–69	27	11 (40.7)	14 (51.9)	2 (7.4)
70–79	32	16 (50.0)	13 (40.6)	2 (6.3)
≥80	14	5 (35.7)	3 (21.4)	1 (7.1)
Total	92	35 (38.0)	43 (46.7)	7 (7.6)
Women
PD subtype
Akinetic-rigid	33	3 (9.1)	16 (47.1)	2 (6.1)
Mixed	9	6 (66.7)	3 (33.3)	0 (0)
Tremor-dominant	28	11 (39.3)	9 (32.1)	2 (7.1)
Age at exam (yr)
<60	9	2 (22.2)	8 (88.9)	1 (11.1)
60–69	13	4 (30.8)	4 (30.8)	0 (0)
70–79	37	10 (27.0)	13 (35.1)	1 (2.7)
≥80	11	4 (36.4)	3 (27.3)	2 (18.2)
Total	70	20 (28.6)	28 (40.0)	4 (5.7)
Total (M and F)	162	55 (34.0)	71 (43.8)	11 (6.8)

Values are expressed as n (%), unless otherwise indicated.

^*Mirapex, Requip, Permax, or Parlodel.

^**Comtan and Tasmar.

PD, Parkinson’s disease; COMT, catechol-O-methyltransferase.